Trials / Completed
CompletedNCT01824238
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)
A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effects of anacetrapib (MK-0859) on low-density lipoprotein-cholesterol (LDL-C) when compared to placebo in Japanese participants with heterozygous familial hypercholesterolemia when added to an existing statin lipid-modifying therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anacetrapib | |
| DRUG | Placebo for anacetrapib |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2014-05-01
- Completion
- 2014-05-01
- First posted
- 2013-04-04
- Last updated
- 2016-04-25
Source: ClinicalTrials.gov record NCT01824238. Inclusion in this directory is not an endorsement.